Swiss National Bank Has $10.23 Million Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

Swiss National Bank trimmed its position in Revolution Medicines, Inc. (NASDAQ:RVMD) by 0.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 225,531 shares of the company’s stock after selling 1,300 shares during the period. Swiss National Bank owned approximately 0.14% of Revolution Medicines worth $10,228,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in Revolution Medicines by 55.8% during the 3rd quarter. GAMMA Investing LLC now owns 620 shares of the company’s stock worth $28,000 after buying an additional 222 shares in the last quarter. Values First Advisors Inc. bought a new stake in shares of Revolution Medicines in the third quarter valued at approximately $93,000. Nisa Investment Advisors LLC grew its holdings in shares of Revolution Medicines by 10.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,378 shares of the company’s stock worth $131,000 after purchasing an additional 320 shares in the last quarter. KBC Group NV grew its stake in Revolution Medicines by 12.9% during the third quarter. KBC Group NV now owns 3,221 shares of the company’s stock worth $146,000 after buying an additional 368 shares in the last quarter. Finally, Amalgamated Bank boosted its position in shares of Revolution Medicines by 7.4% during the 2nd quarter. Amalgamated Bank now owns 5,272 shares of the company’s stock worth $205,000 after acquiring an additional 365 shares in the last quarter. 94.34% of the stock is currently owned by institutional investors.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, insider Mark A. Goldsmith sold 10,000 shares of Revolution Medicines stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $44.93, for a total transaction of $449,300.00. Following the transaction, the insider now directly owns 300,170 shares of the company’s stock, valued at $13,486,638.10. The trade was a 3.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Barbara Weber sold 5,200 shares of the stock in a transaction dated Tuesday, October 8th. The shares were sold at an average price of $48.02, for a total transaction of $249,704.00. Following the completion of the sale, the director now owns 13,065 shares of the company’s stock, valued at approximately $627,381.30. This represents a 28.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 127,866 shares of company stock valued at $6,355,624 over the last ninety days. 8.00% of the stock is currently owned by insiders.

Revolution Medicines Trading Down 0.1 %

NASDAQ RVMD opened at $56.75 on Monday. The company has a market cap of $9.55 billion, a P/E ratio of -15.81 and a beta of 1.40. The company has a fifty day simple moving average of $50.55 and a 200 day simple moving average of $44.62. Revolution Medicines, Inc. has a 12-month low of $20.98 and a 12-month high of $62.40.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.05). During the same quarter in the previous year, the business posted ($0.99) EPS. Sell-side analysts predict that Revolution Medicines, Inc. will post -3.51 EPS for the current year.

Analyst Upgrades and Downgrades

RVMD has been the topic of a number of recent analyst reports. Barclays lifted their target price on Revolution Medicines from $54.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday, September 27th. Piper Sandler increased their target price on shares of Revolution Medicines from $57.00 to $70.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Wedbush reiterated an “outperform” rating and set a $59.00 price target on shares of Revolution Medicines in a report on Thursday, August 8th. HC Wainwright boosted their price objective on Revolution Medicines from $62.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, Oppenheimer raised their target price on Revolution Medicines from $55.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday, October 28th. Eleven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $61.00.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.